Navigation Links
Verenium Reports Financial Results for the Third Quarter 2010
Date:11/9/2010

CAMBRIDGE, Mass., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the third quarter of 2010.

"I am pleased with the significant progress made across the business over the last quarter; we continue to see solid progress growing and diversifying our product sales and improved performance at the gross margin level," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "Further, we remain committed to using our financial resources to accelerate the development of our current products and our pipeline."

Company HighlightsDuring 2010 Verenium has made significant progress on both the operational and financial fronts.  Most recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Achieved a 34% increase in 2010 year-to-date profit share from Phyzyme sales over the same period in 2009 due to strong demand for Phyzyme phytase.

  • Grain Processing

  • Launched Deltazym® GA L-E5 for fuel ethanol production, which together with Fuelzyme, allows us to satisfy the complete enzyme requirements of corn ethanol producers; and
  • Grew 2010 year-to-date revenues from the Company's grain processing enzymes, including Fuelzyme, Deltazym, Veretase and Xylathin, by 37% over the same period in 2009; grain processing has grown to represent more than 25% of 2010 year-to-date product revenues.

  • Oilseed Processing

  • Received regulatory approval for sale of Purifine® PLC in China, completing the product's approval for sale in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United S
    '/>"/>

  • SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
    2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
    3. Verenium Announces Regulatory Approval for Purifine® PLC in China
    4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
    5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
    6. Verenium Announces Proposed Public Offering of Common Stock
    7. Verenium 1:12 Reverse Stock Split Takes Effect
    8. Verenium Announces Reverse Stock Split to Take Effect September 9
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Completes Amendment to 8% Senior Convertible Notes
    11. Verenium Announces Organizational Changes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
    (Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
    (Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
    (Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
    Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
    ... COPENHAGEN and OSLO, September 1 Affitech ... announced that it,has appointed two experienced biotech executives ... CEO of Celldex Therapeutics Inc., has today,assumed overall ... Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca ...
    ... CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and oncology, ... Medical Officer, Paul Blake, M.D., will present a corporate ... Global Investment Conference on Wednesday, September 9, 2009 at ...
    ... ... stem cell research and manufacturing, announced today that it has been granted a license ... human clinical trials. This Drug Manufacturing License recognizes Stemedica as being compliant with ... , ...
    Cached Biology Technology:Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 3
    (Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
    (Date:7/24/2014)... NJIT this week for an all-day public forum on ... Agency (EPA) to dredge toxic sediment from an eight-mile ... has called the plan, which proposes removing 4.3 million ... the riverbed, one of the largest cleanups in the ... disposed off-site. , "We need to ensure the future ...
    (Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
    Breaking Biology News(10 mins):Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
    ... director's cut. In much the same way that numerous films ... footage, a molecular process called alternative splicing enables a single ... created by a team of researchers at Rockefeller University and ... Nature, shows for the first time how the specific location ...
    ... Hopkins and from the University of Milan have effectively ... in mice using a protein that selectively induces positive ... cancer stem cells. The report is published this week ... cancer-glioblastoma-is marked by the presence of these stem-cell-like brain ...
    ... have found that how much detail one remembers of an ... is activated to "package" the memory. , The research may ... an experience such as a car accident, and yet vividly ... , In experiments using functional magnetic resonance imaging (fMRI), the ...
    Cached Biology News:RNA map provides first comprehensive understanding of alternative splicing 2RNA map provides first comprehensive understanding of alternative splicing 3RNA map provides first comprehensive understanding of alternative splicing 4Natural protein stops deadly human brain cancer in mice 2Memories: It's all in the packaging, scientists say 2
    Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
    This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
    ... large numbers of samples may be carried out ... operator attention. System control and data processing ... 4900. The elegant, powerful and very easy ... Windows 98 and 2000., The supplied detector is ...
    Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
    Biology Products: